Publications by authors named "M C Danni"
Article Synopsis
- - The study analyzed the factors behind treatment changes in 4,739 patients with active relapsing-remitting and secondary progressive multiple sclerosis from the Italian MS Register, focusing on those who experienced relapses within the past two years.
- - Results revealed that over half of the patients switched their disease-modifying therapy (DMT) due to clinical relapses, with those who switched being typically younger and less disabled than non-switchers.
- - The use of high-efficacy DMTs, particularly anti-CD20 drugs like Alemtuzumab and Ocrelizumab, was shown to significantly lower the risk of needing to switch treatments due to disease activity.
Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis (PPMS) has been evaluated during phase 3 trials that enrolled patients under 55 years with a maximum Expanded Disability Status Scale (EDSS) of 6.5.
View Article and Find Full Text PDFArticle Synopsis
- A study involving 68 multiple sclerosis patients treated with alemtuzumab tracked the production of T and B lymphocytes over a 48-month period.
- Initially, new T lymphocyte levels dropped significantly three months after treatment, but by 36 months, they peaked, indicating a strong recovery of thymic function.
- B cell production also increased, exceeding baseline levels as soon as three months after starting the treatment, with variations in cellular recovery patterns unrelated to factors like age, sex, previous treatments, or disease outcomes.
Background: Multiple sclerosis (MS) is characterized by phenotypical heterogeneity, partly resulting from demographic and environmental risk factors. Socio-economic factors and the characteristics of local MS facilities might also play a part.
Methods: This study included patients with a confirmed MS diagnosis enrolled in the Italian MS and Related Disorders Register in 2000-2021.
Impact of Dimethylfumarate on Sleep in Multiple Sclerosis Patients: An Actigraphic Study.
CNS Neurol Disord Drug Targets
May 2023
Background: Sleep disorders in multiple sclerosis (MS) patients are common. Dimethylfumarate is an oral disease-modifying drug (DMT), whose impact on sleep is unknown.
Objective: The aim of this study was to characterize actigraphic patterns in MS patients treated with dimethylfumarate.